ProteoNic and NecstGen partner to improve efficiency in manufacturing viral vectors for gene therapies


LEIDEN, Netherlands, April 26, 2022 /PRNewswire/ — ProteoNic, a leading provider of high-end vector technologies and services for the efficient production of biologics, and NecstGen, a CDMO and center of excellence for cell and gene therapy, announce a partnership for the development of better manufacturing of viral vectors for therapy applications. Both companies, located at the Leiden Bio Science Park, recognize the need to increase viral titers and optimize production processes. Cost-effectiveness and manufacturing yield play a critical role in the feasibility of vector-based therapies. Through their combined efforts, ProteoNic and NecstGen aim to improve and advance AAV and LV viral vector manufacturing technology and increase production capacity, ultimately benefiting patients in need of gene therapies.

ProteoNic will apply its established 2G UNicMT technological platform to improve the performance of viral vectors. NecstGen, which specializes in the manufacture and development of different types of viral vectors, brings its viral vector platforms, manufacturing processes and experts to this partnership. Ultimately, companies are working to accelerate new gene therapies by removing existing barriers related to efficiency and production capacity.

Frank PieperCEO of ProteoNic commented, “ProteoNic has a strong track record of improving vector performance and production levels across a range of applications. We believe that with NecstGen, we can improve the efficiency of the production of viral vectors for gene therapy, and thus alleviate the current manufacturing constraints.

Paul Bilars, CEO of NecstGen said, “This action shows the strength and importance of the local ecosystem, and how, working together, we can meet the challenges of gene therapy development and translating them into solutions for patients and society.

About ProteoNic

ProteoNic is a private company with offices in Leiden, the Netherlands and in the Boston region, UNITED STATES. The company offers technology and services for the generation of cell lines with greatly improved production characteristics, including production levels and stability. The company markets its proprietary 2G UNic™ technology through license and partnership agreements. For more information, see

About NectGen

NecstGen is a new center of excellence for cell and gene therapy, located in a purpose-built GMP facility on the largest bio-cluster in the Netherlands, Leiden Bio Science Park. Here, NecstGen provides essential contract development, manufacturing and leasing services to academic and small/large industrial therapy developers to deliver a new generation of therapies to patients. For more information, visit

For more information please contact:


Marc Posnodoctorate
Vice President Business Development
Such. : +1 617 480 8016
E: [email protected]


Tristan Pritchard Meakerdoctorate
Business Development Manager
E: [email protected]

SOURCE ProteoNic


Comments are closed.